Spruce Biosciences
SPRB
31 hedge funds and large institutions have $4.69M invested in Spruce Biosciences in 2024 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 8 reducing their positions, and 4 closing their positions.
75% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 4
7% more funds holding
Funds holding: 29 → 31 (+2)
27% less capital invested
Capital invested by funds: $6.41M → $4.69M (-$1.71M)
50% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 8
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$489K |
| 2 |
BFM
Boothbay Fund Management
New York
|
+$141K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$42K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$28.8K |
| 5 |
HF
HRT Financial
New York
|
+$18.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Almitas Capital
Santa Monica,
California
|
-$188K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$104K |
| 3 |
Renaissance Technologies
New York
|
-$99.6K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$36.6K |
| 5 |
SCV
Sands Capital Ventures
Arlington,
Virginia
|
-$34.8K |
SPRB Hedge Fund Activity: Q4 2024 in Review
31 of the 7,599 institutional investors tracked by Wall St. Rank reported a position in Spruce Biosciences (SPRB) for Q4 2024, worth a combined $4.69M — down 27% from $6.41M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new SPRB positions and 4 closed out — a net gain of 3 holders — while 4 added to existing stakes and 8 trimmed.
The largest buyer was Ikarian Capital, opening a new position worth an estimated $489K. The largest seller was Almitas Capital, exiting entirely with an estimated $188K sold.
- 31 institutional investors held Spruce Biosciences (SPRB) as of Q4 2024, up from 29 in Q3 2024.
- Funds reported $4.69M of Spruce Biosciences stock for Q4 2024, down 27% quarter-over-quarter.
- 7 funds opened new Spruce Biosciences positions in Q4 2024 and 4 closed out, a net change of +3 holders.
- The largest Spruce Biosciences buyer in Q4 2024 was Ikarian Capital, an estimated $489K added.
- The largest Spruce Biosciences seller in Q4 2024 was Almitas Capital, an estimated $188K sold.
Based on aggregated 13F filings for Q4 2024.